Oregon § 646A.697 Study of market for generic drugs; effect of pricing on insurance premiums; report to Legislative Assembly

Oregon Statutes

§ 646A.697 — Study of market for generic drugs; effect of pricing on insurance premiums; report to Legislative Assembly

Oregon § 646A.697

Vol.16

Title 50Trade Regulations and Practices

Ch. 646ATrade Regulation

This text of Oregon § 646A.697 (Study of market for generic drugs; effect of pricing on insurance premiums; report to Legislative Assembly) is published on Counsel Stack Legal Research, covering Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Or. Rev. Stat. § 646A.697 (2026).

Text

(1)As used in this section, “generic drug” means:

(a)A retail drug that is marketed or distributed in accordance with an abbreviated new drug application approved under 21 U.S.C. 355(j);

(b)An authorized generic as defined by 42 C.F.R. 447.502; or

(c)A drug that entered the market before 1962 that was not originally marketed under a new drug application.

(2)The status of the generic drug market includes but is not limited to:

(a)The prices of generic drugs on a year-to-year basis;

(b)The degree to which generic drug prices affect insurance premiums;

(c)Annual changes in health insurance cost-sharing for generic drugs;

(d)The potential for and history of generic drug shortages; and

(e)The degree to which generic drug prices affect annual spending in the state medical assistance pr

Free access — add to your briefcase to read the full text and ask questions with AI

(1) As used in this section, “generic drug” means:
(a) A retail drug that is marketed or distributed in accordance with an abbreviated new drug application approved under 21 U.S.C. 355(j);
(b) An authorized generic as defined by 42 C.F.R. 447.502; or
(c) A drug that entered the market before 1962 that was not originally marketed under a new drug application.
(2) The status of the generic drug market includes but is not limited to:
(a) The prices of generic drugs on a year-to-year basis;
(b) The degree to which generic drug prices affect insurance premiums;
(c) Annual changes in health insurance cost-sharing for generic drugs;
(d) The potential for and history of generic drug shortages; and
(e) The degree to which generic drug prices affect annual spending in the state medical assistance program. [2021 c.598 §6; 2025 c.166 §4]
(Foreclosure Consultants)